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Abstract NRF2 is a nuclear transcription factor activated
in response to oxidative stress and related with metabo-
lizing of xenotoxic materials and ABC transporter medi-
ated drug resistance. We studied the expression of mRNAs
under the siRNA-mediated knockdown of NRF2 and
tBHQ-treated condition in AsPC-1 metastatic pancreatic
cancer cell line to understand the AsPC-1 specific role(s) of
NRF2 and further to investigate the relationship between
drug resistance and metastatic plasticity and mobility of
AsPc1. Here we show that the genes of aldo–keto reduc-
tases, cytochrome P450 family, aldehyde dehydrogenase,
thioredoxin reductase, ABC transporter and epoxide
hydrolase responsible for drug metabolism or oxidative
stress concisely responded to NRF2 stabilization and
knockdown of NRF2. In addition the expression of PIR, a
candidate of oncogene and KISS1, a suppressor of metas-
tasis were affected by NRF2 stabilization and knockdown.
Our result provide comprehensive understanding of NRF2
target genes of drug response, oxidative stress response and
metastasis in AsPc-1 metastatic pancreatic cancer cell line.
Keywords NRF2  tBHQ  AsPC-1  Pancreatic cancer 
Oxidative stress  Drug metabolism
Introduction
Every cell is inevitably exposed to extracellular and
intracellular oxidative stress, every moment (Finkel 2011;
Ma 2010). The nuclear factor erythroid 2-related factor 2
(NRF2 or NFE2L2) is a master transcription factor that
activates a battery of genes which have roles in oxidative
stress responses, detoxifications, and drug resistances
(Bryan et al. 2013; Ma 2013; Mitsuishi et al. 2012; Niture
et al. 2014). NRF2 binds to a DNA element, named anti-
oxidant response element (ARE), in the promoter regions
of its target genes to activate transcription of these genes
(Nguyen et al. 2003). The target genes of NRF2 includes
(a) antioxidant genes such as NAD(P)H dehydrogenase
[quinone] 1 (NQO1), heme oxygenase (decycling) 1
(HMOX1), superoxide dismutase [Cu–Zn] (SOD1), and
glutamate-cysteine ligase catalytic subunit (GCLC);
(b) detoxification genes including glutathione S-transferase
A3 (GSTA3) and thioredoxin reductase 1, cytoplasmic
(TXNRD1); (c) and drug resistance genes such as ATP-
binding cassette sub-family G member 2 (ABCG2) and
ATP-binding cassette, sub-family C (CFTR/MRP), mem-
ber 5 (ABCC5) (Malhotra et al. 2010; Nguyen et al. 2003).
Reactive oxygen species (ROS), which are produced by
various exogenous or endogenous sources, are double-edge
swords. Under tight cellular control, ROS act as important
signaling molecules to regulate diverse cellular functions
including transcriptional regulation and signal transduction
(Corcoran and Cotter 2013; Finkel 2011; Jennings et al.
2013; Ma 2010; Ray et al. 2012). On the contrary uncon-
trolled production of ROS causes various human diseases
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through DNA damage and impaired cellular functions via
oxidative stress (Acharya et al. 2010; Caputo et al. 2012;
Kakehashi et al. 2013; Kryston et al. 2011; Saeidnia and
Abdollahi 2013; Storr et al. 2013). As an ROS sensor, the
level of NRF2 is tightly regulated by a set of proteins
through proteasome-dependent proteloysis. The well-
known negative regulator of NRF2 is the Kelch-like ery-
throid cell-derived protein with CNC homology-associated
protein 1 (KEAP1). KEAP1 binds and destabilized NRF2
through ubiquitin-dependent proteasomal degradation
under normal reducing condition (Bryan et al. 2013; Mit-
suishi et al. 2012; Niture et al. 2014; Storr et al. 2013).
NRF2 stability is also regulated by the CR6-interacting
factor 1 (CRIF1) under both reducing and oxidative stress
conditions (Kang et al. 2010) and the glycogen synthase
kinase 3b (GSK3b)/b-transducin repeat-containing protein
(b-TrCP) axis (Chowdhry et al. 2013; Rada et al. 2011;
Rada et al. 2012). It has been reported that stability of
NRF2 is also regulated by competitive protein–protein
interaction to inhibit NRF2-KEAP1 binding by various
proteins such as p21 (Chen et al. 2009), the Wilms tumor
gene on X chromosome (WTX) (Camp et al. 2012), p62
(Komatsu et al. 2010), the partner and localizer of BRCA2
(PALB2) (Ma et al. 2012), the dipeptidyl peptidase III
(DPP3) (Hast et al. 2013), and the breast cancer suscepti-
bility gene 1 (BRCA1) (Gorrini et al. 2013).
NRF2 functions as either a protector against tumori-
genesis or oncogene (DeNicola et al. 2011; Kensler and
Wakabayashi 2010; Loboda et al. 2008; Muller and
Hengstermann 2012). Stability and activity of NRF2 is
important in human diseases, especially in cancers. While
NRF2 decreases tumor susceptibility in most carcinogen-
esis models, constitutive activation of NRF2 may enhance
tumor cell proliferation and/or confer drug resistance in
lung, pancreatic as well as colorectal cancer cells (Arlt
et al. 2013; Bryan et al. 2013; Duong et al. 2014b; Homma
et al. 2009; Hong et al. 2010; Lister et al. 2011; Mitsuishi
et al. 2012; Niture et al. 2014; Singh et al. 2008; Storr et al.
2013; Yamadori et al. 2012). Indeed, NRF2 is up-regulated
in many types of tumors through somatic mutations that
block KEAP1-dependent regulation of NRF2 stability
(Mitsuishi et al. 2012; Niture et al. 2014; Storr et al. 2013).
Targeting NRF2 either by RNA interference or by small
molecules inhibited tumor growth and increased efficacy of
chemotherapy (Singh et al. 2008) or EGF-driven prolifer-
ation (Yamadori et al. 2012) in non-small cell lung cancer
models and reduced the proliferation and drug-resistance in
human lung cancer cells (Homma et al. 2009) or human
pancreatic cancer cells (Arlt et al. 2013; Duong et al.
2014b; Hong et al. 2010; Lister et al. 2011). Additionally in
primary murine cell models, oncogenes including K-Ras,
B-Raf, and Myc increased the transcription of Nrf2 gene to
activate antioxidant and detoxification program preferable
for oncogenesis (Kang et al. 2014). Under these conditions,
genetic targeting of K-RasG12D-driven Nrf2 impaired
in vivo tumorigenesis (Kang et al. 2014). Taken together,
genome-wide analysis of NRF2-responsive genes in spe-
cific cancer types will give insights on the context-depen-
dent roles of NRF2. In this work we delineated NRF2-
responsive genes in As-PC1 pancreatic cancer cell lines
established from metastatic cancer cell in ascites fluid
(Chen et al. 1982).
Materials and methods
Cell culture and reagents
AsPC-1 cells were obtained from the Korean Cell Line
Bank (Seoul, Korea) and maintained in RPMI-1640 media
(HyClone, Logan, UT) supplemented with 20 % FBS
(Invitrogen, Carlsbad, CA) and 100 U/ml penicillin/strep-
tomycin (Welgene, Daegu, Korea). The cells were cultured
in a humidified 5 % CO2 incubator at 37 C. The cell
viability and cell counting were assessed by the Luna
Automated Cell Counter (Logos Biosystems, Gyunggi-do,
Korea). Tert-butylhydroquinone (tBHQ) was purchased
from Sigma (St. Louis, MO) and stored at -20 C dis-
solved in DMSO with small aliquots.
siRNA transfection
For NRF2 knockdown, exponentially proliferating cells
were transfected with synthesized control siRNA (50-gac-
gagcggcacgugcacauu-30) or NRF2 specific siRNA (50-gag-
uaugagcuggaaaaacuu-30) (Hong et al. 2010), both
purchased from Bioneer (Daejeon, Korea) using Lipofect-
amine 2000 (Invitrogen) according to the manufacturer’s
protocol.
Cell cycle analysis
Cell cycle analysis was carried out by propidium iodide
staining and laser detection of FL2 signal using FAC-
SCalibur (BD Science, Franklin Lakes, NJ), and the data
were analyzed by CellQuest Pro software (BD Science).
After treatment (72 h for siRNA and 16 h for tBHQ
treatment respectively), cells were washed with PBS, fixed
70 % ethanol, and stained with propidium iodide solution
(20 lg/ml) containing RNaseA (100 lg/ml) after removal
of ethanol.
RNA extraction
Total RNA from AsPC-1 cell lines were prepared with the
RNeasy Mini kit (Qiagen, Valencia, CA) according to the
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Fig. 1 Cell cycle analysis of NRF2 siRNA-treated or tBHQ-treated
AsPC-1 cell line. a A representative image of FL2 histogram of FACS
analysis. The figure in the lower right quadrant is combined FACS
analysis images with notion of 2 and 4 N nuclear ploidy. b Immu-
noblot anaylysis of tBHQ-treated (100 lM 16 h) or siRNA-treated
samples (72 h). AsPC-1 cells were seeded in 6-well plates and treated
with tBHQ (or DMSO) or NRF2 siRNA (or control siRNA). Cells
were harvested and whole cell lysates were prepared, electrophoresed
and transferred onto PVDF membranes. Immunoblotting was per-
formed with indicated antibodies and Erk-1 was used as loading
control
Genes Genom (2015) 37:97–109 99
123
manufacturer’s protocols. The purity and integrity of RNA
sample was evaluated by determining the OD260/230 ratio,
28S/18S ratio, peak pattern and electrophoretic migration
patterns on Agilent 2100 Bioanalyzer (Agilent Technolo-
gies, Palo Alto, CA).
Western blot analysis
After 72 h of siRNA treatment or 16 h of tBHQ treatment,
AsPC-1 cells were lysed in 10 mM Tris–HCl (pH 7.0),
100 mM NaCl, 1 % triton X-100, 1 mM DTT, 20 lg/ml
aprotinin, 2.5 lg/ml leupeptin, and 0.5 mM PMSF. Lysates
were resolved on 10 % sodium dodecyl sulfate–polyacryl-
amide by gel electrophoresis (SDS-PAGE) and transferred
onto 0.45 lm pore size Polyvinylidene fluoride (PVDF)
membranes (Millipore, Bedford, MA), and immunoblotted
with following antibodies: Cyclin B1 antibody (CST#4135,
Cell Signaling Technology, Danvers, MA), Cyclin D1 (CST
#2922, Cell Signaling Technology), NRF2 (sc-103032,
Santa Cruz Biotechnology, Santa Cruz, CA), Erk-1 (sc-94,
Santa Cruz Biotechnology), Cyclin A (sc-239, Santa Cruz
Biotechnology). Horseradish peroxidase (HRP)-conjugated
goat anti-rabbit (sc-2004, Santa Cruz Biotechnology) or
anti-mouse antibodies (sc-2005, Santa Cruz Biotechnology)
were used as secondary antibodies.
cDNA microarray analysis
The cDNA microarray analysis was carried out with fluo-
rescence labeling of cRNA and hybridization using
4 9 44 K Human whole genome microarray (Agilent
technologies, Palo Alto, CA) for tBHQ treated cells. For
cDNA microarray analysis of NRF2 siRNA treated cell,
Ilumina Biochip system (HT-12) was used. For each
microarray three RNA samples of independent experiment
were used.
Statistical analysis
Data were analyzed by either Student’s t test (tBHQ treated
sample) or LPE test (siRNA treated sample) (Jain et al.
2003) and the results have been expressed p values and
mean values.
Results and discussion
The AsPC-1 pancreatic cancer cell line, used in this work
had been established from metastatic abdominal ascites fluid
cells originated from metastatic pancreatic cancer (Chen
et al. 1982). It contains well known mutations of pancreatic
Fig. 2 Hierarchical cluster image of the gene expression profiles of
cDNA microarray analysis. a cDNA array of NRF2 siRNA-treated
(2TRE, 3 TRE, 4 TRE) and control siRNA-treated sample (2 Con,
3 Con, 4 Con). Each mRNA sample was labeled and hybridized with
cDNA array chip (HT 12, Ilumina) and cluster analysis was carried
out. b cDNA array of tBHQ-treated versus DMSO-treated AsPC-1
cells. Two sets of mRNA (tBHQ vs DMSO) with triplicate samples
were labeled differently and hybridized. The red color indicated up-
regulated genes and the green color indicates down-regulated genes
100 Genes Genom (2015) 37:97–109
123
Table 1 List of genes with (57 records) with more than two fold increase (p \ 0.05) in tBHQ-treated AsPC-1 cells
Probe ID (Agilent 44 k) Gene symbol Fold change p Value Gene name
A_23_P415015 ATL2 10.528 5.52E-04 Atlastin GTPase 2
A_33_P3416588 RIT2 10.341 6.05E-04 Ras-like without CAAX 2
A_23_P83134 GAS1M 4.752 1.13E-03 Growth arrest-specific 1
A_33_P3257155 SMAP1 4.697 4.41E-05 Small ArfGAP 1
A_24_P129341 AKR1B10D, O 4.694 8.83E-04 Aldo–keto reductase family 1, member B10
A_23_P93641 AKR1B10D, O 4.652 8.91E-04 Aldo–keto reductase family 1, member B10
A_33_P3272628 FCER1GD 4.621 1.31E-04 Fc fragment of IgE, high affinity I, receptor for;
gamma polypeptide
A_23_P258190 AKR1B1D, O 4.588 9.03E-04 Aldo–keto reductase family 1, member B1
A_23_P80570 AADACD 4.488 9.31E-04 Arylacetamide deacetylase (esterase)
A_33_P3244640 GRK5D, M 4.433 1.06E-03 G protein-coupled receptor kinase 5
A_33_P3380992 AKR1B15D 4.415 9.39E-04 Aldo–keto reductase family 1, member B15
A_33_P3304688 TNAP 4.272 1.06E-03 TRAFs and NIK-associated protein
A_23_P404162 HDAC9D, O, M 4.176 1.07E-03 Histone deacetylase 9
A_33_P3254751 LOC100131355 3.703 1.67E-03 Hypothetical protein LOC100131355
A_33_P3265394 WDR74 3.071 2.51E-03 WD repeat domain 74
A_23_P257971 AKR1C1 D, O, M 3.005 1.59E-03 Aldo–keto reductase family 1, member C1
A_23_P323143 ZNF767 2.919 1.76E-04 Zinc finger family member 767
A_33_P3350853 LOC202781 2.885 1.74E-04 Hypothetical LOC202781
A_23_P96623 OPN1MW 2.879 2.65E-03 Opsin 1 (cone pigments), medium-wave-sensitive
A_33_P3396956 C1orf172 2.874 1.87E-03 Chromosome 1 open reading frame 172
A_23_P67453 TNNI3 2.846 2.95E-04 Troponin I type 3 (cardiac)
A_23_P46238 CELA2A 2.823 2.08E-03 Chymotrypsin-like elastase family, member 2A
A_24_P943949 LRRC8B 2.775 3.48E-03 Leucine rich repeat containing 8 family, member B
A_23_P125042 ZNF222 2.763 3.62E-03 Zinc finger protein 222
A_33_P3268234 KRT39 2.692 3.44E-03 Keratin 39
A_32_P180741 TNK2 2.690 3.52E-03 Tyrosine kinase, non-receptor, 2
A_24_P68908 LOC344887 2.600 2.11E-03 Similar to hCG2041270
A_33_P3314401 CLDN16 2.580 3.96E-03 Claudin 16
A_33_P3365117 AKR1C1D, O, M 2.563 4.45E-03 Aldo–keto reductase family 1, member C1
A_24_P152968 AKR1C1D, O, M 2.562 2.18E-03 Aldo–keto reductase family 1, member C1
A_23_P63432 RHBDL2 2.509 2.89E-03 Rhomboid, veinlet-like 2 (Drosophila)
A_33_P3294277 CYP4F3D 2.489 2.59E-03 Cytochrome P450, family 4, subfamily F, polypeptide 3
A_23_P28697 HAAO 2.394 4.38E-03 3-hydroxyanthranilate 3,4-dioxygenase
A_24_P678418 DICER1-AS 2.378 2.74E-03 Hypothetical locus FLJ45244
A_23_P46222 TRIM46 2.370 2.85E-03 Tripartite motif containing 46
A_33_P3389363 C19orf54 2.364 3.17E-03 Chromosome 19 open reading frame 54
A_23_P502047 CHRD 2.345 3.99E-03 Chordin
A_23_P50710 CYP4F2D 2.340 4.52E-03 Cytochrome P450, family 4, subfamily F, polypeptide 2
A_33_P3315239 ZNF7 2.337 4.01E-03 Zinc finger protein 7
A_33_P3336287 SEC61A2 2.322 4.20E-03 Sec61 alpha 2 subunit (S. cerevisiae)
A_23_P301521 KIAA1462 2.275 6.97E-03 KIAA1462
A_33_P3420900 PATE2 2.272 1.54E-03 Prostate and testis expressed 2
A_23_P218793 XPNPEP3 2.187 3.38E-03 X-prolyl aminopeptidase (aminopeptidase P) 3, putative
A_33_P3265714 C2orf61 2.184 1.05E-02 Chromosome 2 open reading frame 61
A_33_P3252381 PCA3 2.167 1.36E-03 Prostate cancer antigen 3 (non-protein coding)
A_33_P3378915 ARHGEF18 2.164 3.58E-03 Rho/Rac guanine nucleotide exchange factor (GEF) 18
A_33_P3397520 KRTAP10-12 2.137 4.86E-03 Keratin associated protein 10-12
A_24_P307135 TNXB 2.111 7.60E-03 Tenascin XB
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cancer including, KRAS (p.G12D), TP53 (p.C135fsP35),
SMAD4 (p.R100T), and other mutations common in cancers
as well: COL2A1 (c.915 ? 3A [ G), FBXW7 (p.R465C),
HEY1 (p.I178V), KIF5B (p.Q467K), MLL (p.P3536H),
RNF43 (p.S720*) (Deer et al. 2010). The relative expression
level of NRF2 between various pancreatic cancer cell lines
including immortalized human pancreatic ductal epithelial
cell lines (HPDE) using GEO2R analysis with pre-deposited
microarray data (Thu et al. 2014) at NCBI Gene Expression
Ominbus (http://www.ncbi.nlm.nih.gov/geo/geo2r/?acc=
GSE40099&platform=GPL6480) is presented in supple-
mentary Fig. 1. NRF2 was reported to be increased in pan-
creatic cancer cell lines and the nuclear level of NRF2 in
AsPC-1 cell line has been reported to be relatively higher
than in immortalized pancreatic ductal epithelial cells (Hong
et al. 2010; Lister et al. 2011).
An antioxidant tBHQ increases the level of NRF2 pro-
tein by stabilization and stimulates the expression of oxi-
dative stress metabolizing genes (Hirose et al. 1993; Li
et al. 2005). Prior to cDNA microarray we tested whether
tBHQ or NRF2 siRNA treatment can change the cell cycle
of AsPC-1 cell line. As shown in Fig. 1a no apparent
change in cell cycle distribution was observed along with
no accumulation of sub G1 population. Immunoblot ana-
lysis also revealed that no apparent change of cell cycle
marker proteins including cyclin B1 and cyclin D. The
level of NRF2 protein was shown to be increased in tBHQ
treated cells and decreased in NRF2 siRNA treated sample
(Fig. 1b).
To identify changed genes upon treatment of 100 lM
tBHQ, we used the Agilent 44 k whole genome cDNA
array chip. We also used the Ilumina HT-12 whole genome
cDNA array chip for NRF2 siRNA mediated gene
expression analysis. Three independent RNA samples were
used in these experiments. After removal of marginal or
absent signal spots, 20,312 positive spots were obtained
from tBHQ-treated sample and 16,423 positive spots were
obtained from NRF2 siRNA-treated sample. Hierarchical
cluster image of NRF2 siRNA treatment samples reveals
that the gene expression pattern of three siRNA-treated
sample and three control siRNA-treated samples are ade-
quately clustered (Fig. 2a). Figure 2b shows the hierar-
chical cluster image of cDNA microarray of tBHQ-treated
sample indicating three independent samples share con-
cordant RNA expression pattern.
Further statistic tests after normalization of positive spots
provide statistically significant 533 array sets from tBHQ-
treated samples (supplementary Table 1) and 189 array sets
from NRF2 siRNA-treated samples (supplementary
Table 2). Table 1 shows a list of genes which show more
than two fold increase of expression (p \ 0.05) after treat-
ment of tBHQ (57 genes). Among them AKR1B10,
FCER1G, AKR1B1, AKR1B15, AADAC, GRK5, HDAC9,
AKR1C1, CYP4F3, CYP4F2, ALDH3A1, FANCD2,
TXNRD1 and SLC7A11 are classified as members of drug
response genes or oxidative stress response genes according
to gene ontology (Table 1). The lists of genes decreased by
tBHQ treatment are listed in Table 2. Four genes classified
as drug response or oxidative stress response genes were
identified: PDE7A, TGM1, CYTH1 and EPS15. The list of
top 50 genes which were decreased by NRF2 siRNA treat-
ment are presented in Table 3. The listing is arbitrary but
these genes showed more than 40 % reduction in expression.
The siRNA mediated knockdown of NRF2 significantly
reduced the expression of oxidative stress or drug response
genes including, AKR1B10, ALDH1A1, HGD, TFF1, GPX2,
ALDH3A1, PPP1R1B, AKR1C4, ABCB6, ABCC3, NFE2L2,
EPHX1, ASGR1, SLC2A5, LGALS1 and MTR (Table 3). The
expression of NRF2 itself was significantly (p \ 0.001,
50 % reduction) decreased by the treatment of siRNA
reflecting the reliable quality control of siRNA treatment.
On the contrary to NRF2 siRNA treatment the change of
Table 1 continued
Probe ID (Agilent 44 k) Gene symbol Fold change p Value Gene name
A_33_P3259548 WDR5B 2.097 4.74E-03 WD repeat domain 5B
A_23_P38190 ORMDL3 2.084 4.14E-03 ORM1-like 3 (S. cerevisiae)
A_23_P3956 C1QTNF1 2.069 3.97E-03 C1q and tumor necrosis factor related protein 1
A_33_P3238433 ALDH3A1D, O 2.063 3.96E-03 Aldehyde dehydrogenase 3 family, memberA1
A_23_P345678 FANCD2D, O, M 2.046 5.27E-03 Fanconi anemia, complementation group D2
A_33_P3351120 TXNRD1D,O 2.042 4.10E-03 Thioredoxin reductase 1
A_33_P3258581 LOC389791 2.032 5.19E-03 Hypothetical LOC389791
A_33_P3242623 SLC7A11D, M 2.011 4.31E-03 Solute carrier family 7, member 11
A_24_P223163 NAF1 2.006 4.47E-03 Nuclear assembly factor 1 homolog (S. cerevisiae)
The fold increased/decreased values are mean of three independent samples. Superscripts were assigned to drug response genes (D), oxidative
stress response genes (O) and metastasis (M) related genes according to gene ontology. These gene symbols are presented in bold style
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Table 2 Top 50 gene records with decreased expression (p \ 0.05) in tBHQ-treated AsPC-1 cells
Probe ID (Agilent 44 k) Symbol Fold change p Value Gene name
A_23_P337849 CELF3 0.398 1.10E-02 CUGBP, Elav-like family member 3
A_24_P322229 RASL10B 0.466 7.41E-03 RAS-like, family 10, member B
A_33_P3213512 COQ5 0.468 1.24E-02 Coenzyme Q5 homolog, methyltransferase (S. cerevisiae)
A_23_P60627 ALOX15BM 0.475 1.30E-02 Arachidonate 15-lipoxygenase, type B
A_33_P3356004 UCKL1-AS1 0.542 3.18E-02 UCKL1 antisense RNA 1 (non-protein coding)
A_33_P3247678 LOC100130876 0.550 7.40E-03 Uncharacterized LOC100130876
A_33_P3245679 LOC100129940 0.554 2.98E-02 Uncharacterized LOC100129940
A_23_P146325 ASAP1-IT1 0.566 9.59E-03 ASAP1 intronic Transcript 1 (non-protein coding)
A_32_P110016 LOC727869 0.567 3.94E-02 Uncharacterized LOC727869
A_23_P59988 SLC35G5 0.567 2.72E-02 Solute carrier family 35, member G5
A_33_P3281363 TRIP12 0.573 1.24E-02 Thyroid hormone receptor interactor 12
A_23_P114445 MAGEE1 0.577 1.23E-02 Melanoma antigen family E, 1
A_24_P360529 PDE7AD 0.589 3.23E-02 Phosphodiesterase 7A
A_23_P18055 C3orf51 0.597 1.85E-02 Chromosome 3 open reading frame 51
A_33_P3544880 LOC142937 0.622 1.05E-02 Uncharacterized protein BC008131
A_33_P3576797 LOC158863 0.622 1.17E-02 Uncharacterized LOC158863
A_24_P314597 KIAA0319L 0.631 1.73E-02 KIAA0319-like
A_33_P3272399 LOC645427 0.632 2.14E-02 Uncharacterized LOC645427
A_33_P3256500 ATXN2 0.636 2.07E-02 Ataxin 2
A_33_P3248265 LTB 0.647 2.48E-02 Lymphotoxin beta (TNF superfamily, member 3)
A_33_P3522511 KIAA0485 0.649 3.41E-02 Uncharacterized LOC57235
A_33_P3319134 LOC100506191 0.649 3.60E-02 Uncharacterized protein LOC100506191
A_24_P693321 LOC100190986 0.649 6.81E-03 Uncharacterized LOC100190986
A_23_P65618 TGM1D 0.653 2.67E-02 Transglutaminase 1
A_33_P3249259 TGM6 0.656 1.57E-02 Transglutaminase 6
A_23_P108932 RPL23AP32 0.658 4.13E-02 Ribosomal protein L23a pseudogene 32
A_33_P3333777 LOC100129387 0.661 3.27E-02 Uncharacterized LOC100129387
A_23_P326142 C7orf54 0.663 3.05E-02 Chromosome 7 open reading frame 54
A_33_P3335840 WDR33 0.666 3.53E-02 WD repeat domain 33
A_33_P3324137 PRO0628 0.668 1.90E-02 Uncharacterized LOC29053
A_33_P3393010 PKDCC 0.669 2.08E-02 Protein kinase domain containing, cytoplasmic
homolog (mouse)
A_33_P3321372 CNTNAP3 0.673 1.20E-02 Contactin associated protein-like 3
A_33_P3250018 HCFC2 0.673 4.56E-02 Host cell factor C2
A_33_P3762913 LOC100216546 0.677 3.29E-02 uncharacterized LOC100216546
A_33_P3223990 TPM3 0.680 3.66E-02 Tropomyosin 3
A_33_P3503937 LOC284581 0.683 1.31E-02 Uncharacterized LOC284581
A_33_P3357382 POGZ 0.685 1.94E-02 Pogo transposable element with ZNF domain
A_33_P3276913 TTC3 0.685 3.02E-02 Tetratricopeptide repeat domain 3
A_33_P3363091 VAC14 0.685 2.87E-02 Vac14 homolog (S. cerevisiae)
A_33_P3356525 FLJ45482 0.686 1.22E-02 Uncharacterized LOC645566
A_33_P3310751 LOC100132249 0.690 4.21E-02 Uncharacterized LOC100132249
A_33_P3345743 PFN1P2 0.691 2.36E-02 Profilin 1 pseudogene 2
A_23_P6561 EBLN2 0.692 1.29E-02 Endogenous Bornavirus-like nucleoprotein 2
A_23_P59613 FZD9M 0.692 1.63E-02 Frizzled family receptor 9
A_33_P3397795 C14orf135 0.694 1.31E-02 Chromosome 14 open reading frame 135
A_33_P3304533 RNF207 0.696 2.21E-02 Ring finger protein 207
A_33_P3380405 CYTH1D 0.699 1.98E-02 Cytohesin 1
A_33_P3538279 PRO2852 0.699 2.61E-02 Uncharacterized protein PRO2852
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Table 2 continued
Probe ID (Agilent 44 k) Symbol Fold change p Value Gene name
A_23_P60793 ASMTL-AS1 0.703 3.95E-02 ASMTL antisense RNA 1 (non-protein coding)
A_33_P3371752 EPS15D, M 0.704 1.52E-02 Epidermal growth factor receptor pathway substrate 15
A_33_P3355371 TTC9C 0.704 3.17E-02 Tetratricopeptide repeat domain 9C
The fold increased/decreased values are mean of three independent samples. Superscripts were assigned to drug response genes (D), oxidative
stress response genes (O) and metastasis (M) related genes according to gene ontology. These gene symbols are presented in bold style
Table 3 Top 50 gene records with decreased expression (p \ 0.05) in NRF2 siRNA-treated AsPC-1 cells
Probe IDIlumina Symbol Fold change p Value (LPE t-test) Gene name
ILMN_1672148 AKR1B10D, O 0.241 0.00E?00 Aldo–keto reductase family 1, member B10 (aldose reductase)*
ILMN_1709348 ALDH1A1D, O, M 0.253 0.00E?00 Aldehyde dehydrogenase 1 family, member A1
ILMN_2096372 ALDH1A1D, O, M 0.358 4.86E-12 Aldehyde dehydrogenase 1 family, member A1
ILMN_2198239 HGDO 0.393 5.28E-08 Homogentisate 1,2-dioxygenase (homogentisate oxidase)
ILMN_1794829 C6orf117 0.410 1.82E-07 Chromosome 6 open reading frame 117
ILMN_1729117 COL5A2 0.418 1.54E-08 Collagen, type V, alpha 2
ILMN_1811387 TFF3M 0.426 0.00E?00 Trefoil factor 3 (intestinal)
ILMN_1781745 C9orf152 0.445 1.43E-06 Chromosome 9 open reading frame 152
ILMN_1722489 TFF1D, O, M 0.445 1.24E-10 Trefoil factor 1
ILMN_1800091 RARRES1 0.465 1.40E-06 Retinoic acid receptor responder (tazarotene induced) 1
ILMN_2133205 GPX2D, O 0.469 3.59E-10 Glutathione peroxidase 2 (gastrointestinal)
ILMN_1702503 ALDH3A1D, O 0.481 3.84E-06 Aldehyde dehydrogenase 3 family, memberA1*
ILMN_2412336 AKR1C2 0.488 3.94E-05 Aldo–keto reductase family 1, member C2
ILMN_2304495 PPP1R1BD, O 0.489 1.57E-05 Protein phosphatase 1, regulatory (inhibitor) subunit 1B
ILMN_1684873 ARSD 0.491 5.26E-05 Arylsulfatase D
ILMN_1772951 ST6GALNAC1 0.492 1.06E-07 ST6 (a-N-acetyl-neuraminyl-2,3-b-galactosyl-1, 3)-N-
acetylgalactosaminide a-2,6-sialyltransferase 1
ILMN_1687757 AKR1C4O 0.506 1.81E-04 Aldo–keto reductase family 1, member C4
ILMN_2193980 ABCB6D 0.509 5.44E-06 ATP-binding cassette, sub-family B (MDR/TAP), member 6
ILMN_2161330 SPDEFM 0.513 2.61E-03 SAM pointed domain containing ets transcription factor
ILMN_1677814 ABCC3D, O 0.518 3.96E-06 ATP-binding cassette, sub-family C (CFTR/MRP), member 3
ILMN_1790909 NFE2L2D, O 0.519 6.27E-04 Nuclear factor (erythroid-derived 2)-like 2
ILMN_1680652 SELENBP1 0.520 3.74E-04 Selenium binding protein 1
ILMN_1756685 DEPDC6 0.523 6.27E-04 DEP domain containing 6
ILMN_1704353 IGSF3 0.525 6.27E-04 Immunoglobulin superfamily, member 3
ILMN_1743620 RARRES1 0.528 1.47E-03 Retinoic acid receptor responder (tazarotene induced) 1
ILMN_1752932 MPZL2 0.532 2.94E-03 Myelin protein zero-like 2
ILMN_1701025 EPHX1D, O 0.535 4.13E-05 Epoxide hydrolase 1, microsomal (xenobiotic)
ILMN_1680738 C5orf13 0.543 6.93E-03 Chromosome 5 open reading frame 13
ILMN_1653956 LOC644624 0.545 6.70E-03 PREDICTED: hypothetical LOC6446241
ILMN_1769013 ASGR1D, O 0.545 2.13E-04 Asialoglycoprotein receptor 1
ILMN_1748352 CTSL2M 0.547 3.16E-03 Cathepsin L2
ILMN_1659984 MEP1A 0.550 3.94E-05 Meprin A, alpha (PABA peptide hydrolase)
ILMN_1736042 ME1 0.551 2.91E-03 Malic enzyme 1, NADP(?)-dependent, cytosolic
ILMN_1779015 ZNF467 0.554 1.05E-03 Zinc finger protein 467
ILMN_1761247 PIRM 0.561 1.83E-02 Pirin (iron-binding nuclear protein)
ILMN_2255579 RAB37 0.565 6.27E-04 RAB37, member RAS oncogene family
ILMN_1726114 SLC45A3 0.566 1.96E-06 Solute carrier family 45, member 3
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Table 3 continued
Probe IDIlumina Symbol Fold change p Value (LPE t-test) Gene name
ILMN_1671337 SLC2A5D, O 0.566 6.19E-03 Solute carrier family 2 (facilitated glc/fruc transporter),
member 5
ILMN_2278335 LOC441282 0.567 4.28E-04 Similar to aldo–keto reductase family 1, member B10
ILMN_1712305 CYBRD1 0.572 6.27E-04 Cytochrome b reductase 1
ILMN_2383383 PIRM 0.576 1.74E-02 Pirin (iron-binding nuclear protein)
ILMN_1657547 CCDC34 0.578 2.33E-04 Coiled-coil domain containing 34
ILMN_1678692 MPRIP 0.579 9.67E-03 Myosin phosphatase Rho interacting protein
ILMN_1723978 LGALS1D, O, M 0.579 5.76E-03 Lectin, galactoside-binding, soluble, 1
ILMN_2087692 CYBRD1 0.581 1.45E-03 Cytochrome b reductase 1
ILMN_1802100 ADAM28 0.587 3.29E-02 ADAM metallopeptidase domain 28
ILMN_1761733 HLA-DMB 0.587 7.93E-03 Major histocompatibility complex, class II, DM beta
ILMN_1695397 LOC644151 0.588 1.64E-03 PREDICTED: similar to calpain 8 (LOC644151)
ILMN_1670801 MTRD, O 0.591 3.80E-02 5-methyltetrahydrofolate-homocysteine methyltransferase
ILMN_1699728 BTD 0.591 1.74E-02 Homo sapiens biotinidase
The fold changes are mean of three independent samples. Superscripts were assigned to drug response genes (D), oxidative stress response genes
(O) and metastasis (M) related genes according to gene ontology. These gene symbols are presented in bold style
Table 4 Top 50 gene records with increased expression (p \ 0.05) in NRF2 siRNA-treated AsPC-1 cells
Probe ID Ilumina Symbol Fold change p Value (LPE t-test) Gene name
ILMN_1796094 CD36D, O, M 4.476 4.78E-25 CD36 molecule (thrombospondin receptor)
ILMN_1784863 CD36D, O, M 3.416 4.13E-13 CD36 molecule (thrombospondin receptor)
ILMN_1656501 DUSP5 2.664 1.24E-08 Dual specificity phosphatase 5
ILMN_1679262 DPYSL3M 2.389 7.67E-11 Dihydropyrimidinase-like 3
ILMN_1693789 ALPPD, O 2.296 1.82E-07 Alkaline phosphatase, placental (Regan isozyme)
ILMN_1700144 ITGA10 2.241 7.76E-06 Integrin, alpha 10
ILMN_1787691 CITED4 2.157 5.80E-06 Cbp/p300-interacting transactivator, with
Glu/Asp-rich carboxy-terminal domain, 4
ILMN_2108735 EEF1A2 2.094 6.43E-03 Eukaryotic translation elongation factor 1 alpha 2
ILMN_1813386 CORO6 2.073 4.73E-05 Coronin 6
ILMN_2368530 IL32M 2.042 1.06E-07 Interleukin 32
ILMN_1776861 HAP1 2.039 2.25E-04 Huntingtin-associated protein 1
ILMN_2317581 SHANK3 2.023 2.48E-05 SH3 and multiple ankyrin repeat domains 3
ILMN_2317580 SHANK3 1.950 1.28E-03 SH3 and multiple ankyrin repeat domains 3
ILMN_2049417 TMEM86B 1.920 8.22E-04 Transmembrane protein 86B
ILMN_1778010 IL32M 1.919 2.26E-04 Interleukin 32
ILMN_1697460 REEP6 1.915 4.15E-03 Receptor accessory protein 6
ILMN_1710553 TMEM151A 1.900 2.61E-03 Transmembrane protein 151A
ILMN_1678086 CCDC74A 1.894 2.68E-03 Coiled-coil domain containing 74A
ILMN_1778401 HLA-BD, O, M 1.878 8.82E-05 Major histocompatibility complex, class I, B
ILMN_1709659 TMEM151A 1.868 1.74E-02 Transmembrane protein 151A
ILMN_1734707 CHST13 1.857 3.42E-03 Carbohydrate (chondroitin 4) sulfotransferase 13
ILMN_1794501 HAS3M 1.840 1.28E-03 Hyaluronan synthase 3
ILMN_1674580 TRIM36 1.834 1.67E-03 Tripartite motif-containing 36
ILMN_1761912 MGAT1 1.824 1.29E-02 Mannosyl (alpha-1,3-)-glycoprotein beta-
1,2-N-acetylglucosaminyl transferase
ILMN_1679267 TGM2D, O, M 1.818 1.28E-03 Transglutaminase 2
ILMN_2136971 FABP3D, O, M 1.815 5.45E-03 Fatty acid binding protein 3, muscle and heart
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NRF2 expression by the tBHQ treatment was not significant
(data not shown) since tBHQ stabilized NRF2 protein but
had no effect on the mRNA level of NRF2. The array results
of increased genes under the NRF2 activated status (tBHQ
treatment) and decreased genes by the NRF2 siRNA treat-
ment seem to be coincide. We listed top 50 gene records
with increased expression upon NRF2 siRNA treatment in
Table 4. Ten genes classified as drug response or oxidative
stress response genes were identified as increasing genes in
NRF2 siRNA treatment: CD36, ALPP, HLA-B, TGM2,
FABP3, CTSH, CYR61, TIMP2, PRNP and NR4A2. We also
analyzed metastasis related genes in Tables 1, 2, 3 and 4.
In the cDNA array data of tBHQ-treated cells and NRF2
siRNA-treated samples, total 18 overlapping genes could be
obtained with statistical significance (p \ 0.05) (Table 5).
Unexceptionally 17 genes with increased mRNA expression
under the tBHQ treatment showed decreased expression by
NRF2 siRNA treatment. The metastasis genes whose
relationship with NRF2 was reported previously are as
follows: AKR1B10 (Agyeman et al. 2012; Nishinaka et al.
2011), ALDH3A1 (Agyeman et al. 2012), TXNRD1 (Sakurai
et al. 2005), AKR1C4 (Ebert et al. 2011), ALDH1A1 (Duong
et al. 2014a), PIR (Hubner et al. 2009), GPX2 (Banning
et al. 2005), UGDH (Loignon et al. 2009), SRXN1 (Soriano
et al. 2008), ME1 (Thimmulappa et al. 2002), ABCB6
(Campbell et al. 2013), EPHX1 (Su et al. 2014), NQO1
(Agyeman et al. 2012; Loignon et al. 2009; Thimmulappa
et al. 2002), and ABCC3 (Adachi et al. 2007). Interestingly,
we identified three new genes including ALDH3A2, ASPH,
and KISS1 as NRF2-responsive genes in this study. To date
no study has been reported the relationship of NRF2 with
ALDH3A2, ASPH, and KISS1. KISS1 is a protein with 145
amino acid residues and its role is known as an inhibitor of
metastasis (Ji et al. 2013). Overexpression KISS1 inhibits
metastatic colony formation in ovarian cancer cell lines
(Jiang et al. 2005). However, the role of KISS1 in pancreatic
Table 4 continued
Probe ID Ilumina Symbol Fold change p Value (LPE t-test) Gene name
ILMN_2077680 CLDND2 1.814 2.15E-03 Claudin domain containing 2
ILMN_1669362 IGFBP6 1.811 3.15E-06 Insulin-like growth factor binding protein 6
ILMN_2361737 TRIM36 1.809 2.94E-03 Tripartite motif-containing 36
ILMN_1805842 FHL1 1.796 1.82E-03 Four and a half LIM domains 1
ILMN_2390853 CTSHD, O 1.780 2.68E-03 Cathepsin H
ILMN_1676712 LOC645553 1.778 1.28E-03 PREDICTED: hypothetical LOC645553
ILMN_2171384 CXCL5M 1.766 1.17E-02 Chemokine (C-X-C motif) ligand 5
ILMN_1780057 RENBP 1.764 6.43E-03 Renin binding protein
ILMN_2188264 CYR61O, M 1.759 5.85E-03 Cysteine-rich, angiogenic inducer, 61
ILMN_1782305 NR4A2O, M 1.744 9.73E-03 Nuclear receptor subfamily 4, group A, member 2
ILMN_1792538 CD7 1.740 3.63E-02 CD7 molecule
ILMN_1705814 KRT80 1.738 9.51E-03 Keratin 80
ILMN_1721876 TIMP2O, M 1.733 3.53E-02 TIMP metallopeptidase inhibitor 2
ILMN_1655915 MMP11M 1.725 2.02E-02 Matrix metallopeptidase 11 (stromelysin 3)
ILMN_1656361 LOC201175 1.722 1.43E-02 Hypothetical protein LOC201175
ILMN_1785646 PMP22 1.720 4.71E-02 Peripheral myelin protein 22
ILMN_1748844 CNKSR3 1.713 1.29E-02 CNKSR family member 3
ILMN_2360415 PRNPO 1.713 2.15E-02 Prion protein (PRNP)2
ILMN_1814296 TRPM6 1.711 2.15E-03 Transient receptor potential cation channel, subfamily
M, member 6
ILMN_1667295 VASN 1.706 1.84E-02 Vasorin
ILMN_1727466 KCNMB4 1.700 5.76E-03 Potassium large conductance calcium-activated channel,
subfamily M, beta member 4
ILMN_2405009 NBL1 1.695 2.38E-02 Neuroblastoma, suppression of tumorigenicity 1
ILMN_1801246 IFITM1 1.694 6.27E-04 Interferon induced transmembrane protein 1 (9–27)
ILMN_2339955 NR4A2O, M 1.688 3.79E-02 Nuclear receptor subfamily 4, group A, member 2
The fold changes are mean of three independent samples. Superscripts were assigned to drug response genes (D), oxidative stress response genes
(O) and metastasis (M) related genes according to gene ontology. These gene symbols are presented in bold style
106 Genes Genom (2015) 37:97–109
123
cancers has not yet been elucidated. Previously, a report
displayed that NRF2 deficient mice showed higher number
of pulmonary metastasis than wild-type mice (Satoh et al.
2010). ShRNA mediated knockdown of NRF2 also
enhanced cellular plasticity and motility in HepG2 cell
(Rachakonda et al. 2010). However, in esophageal squa-
mous cancer cell line NRF2 suppression downregulated the
migration and invasion (Shen et al. 2014). Currently, the
potential role of NRF2 in regulation of metastasis is under
active investigation.
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